A randomized controlled trial of salt-sensitive hypertension treated by SGLT2 inhibitor compared to with CCB

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038105

Enrollment

Unknown

Registered

2020-09-11

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

salt-sensitive hypertensive

Interventions

Grpup A:empagliflozin 10 mg

Group B:Nifedipine controlled release tablet 30mg

Group C:empagliflozin 10 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 140 mmHg and (or) diastolic blood pressure > 90mmHg; 2) 24 hours ambulatory blood pressure > 130/80mmHg. All patients diagnosed as primary hypertention, including taking medicine and those not.

Exclusion criteria

Exclusion criteria: 1. Patients with hypertensive crisis and malignant hypertension; 2. Patient combined with severe heart and lung disease, tumor and other diseases is not suitable for this clinical trial; 3. allergy to SGLT2 inhibitor and CCB.

Design outcomes

Secondary

Measure	Time frame
HCT;electrolyte (sodium);renal function creatine;blood glucose;HbAc;	—

Primary

Measure	Time frame
24h dynamic blood pressure;OBPM;	—

Countries

China

Contacts

Public ContactQiang She

The Second Affiliated Hospital of Chongqing Medical University

qshe98@hotmail.com+86 13508393602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026